Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025Clinical and Experimental MedicineOpen Access

Treatment of refractory non-small cell lung cancer with combined infusion of modified CIK cells and PD1 antibody: safety and efficacy

View Full Paper
Ask AI
Bookmark
Share

Authors

FYFeiyu YunInner Mongolia Medical UniversityMYMark YunInner Mongolia Medical UniversityXLXin LiXihua University

Discussion

Loading...

Member takes

Implication

Clinical study shows safety and efficacy of modified CIK cells combined with PD-1 antibody in refractory NSCLC, indicating potential for improved outcomes.

Key Points

  • Partial remission was achieved in 2 of 12 patients, with 6 showing stable disease after treatment.
  • No serious side effects occurred, and significant increases in anti-tumor cytokines were observed (P < 0.05).
  • Patients experienced improvements in Karnofsky Performance Scale after immunotherapy, indicating better quality of life.
  • Induced NKT-like cells demonstrated strong cytotoxicity against tumor cell lines in vitro when treated with PD-1 antibody.

Cite This Study

Yun et al. (2025) studied this question.

synapsesocial.com/papers/68c23fc3b210217d647975echttps://doi.org/10.1007/s10238-025-01796-8
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Evaluating the efficacy of neoadjuvant immunotherapy combined with chemotherapy for stage IIIa non-small cell lung cancer2025
  2. 2Efficacy and safety of different PD-1 inhibitors as first-line treatment for advanced or metastatic squamous non-small cell lung cancer: A retrospective real-world study2025
  3. 3Autologous Cytokine-induced Killer Cell Combination Therapy Enhances Response to Immune Checkpoint Inhibitors in Patients with Refractory Clear Cell Renal Cell Carcinoma2025
  4. 4Treatment Strategies for First-Line PD-L1-Unselected Advanced NSCLC: A Comparative Review of Immunotherapy-Based Regimens by PD-L1 Expression and Clinical Indication2025 · 3 citations
  5. 5The Applications of PD1 Monoclonal Antibody in Non-small Cell Lung Cancer2025